M-h Stern

Paris, 75013, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Corrections: Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Journal: Leukemia
Published: October 24, 2020

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Journal: Leukemia
Published: July 30, 2019

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Journal: Leukemia
Published: May 26, 2017

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Journal: Nature communications
Published: December 28, 2016

Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Journal: Oncogene
Published: January 08, 2015

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

Journal: Leukemia
Published: January 18, 2014

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.

Journal: Leukemia
Published: September 20, 2013

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.

Journal: Oncogene
Published: September 19, 2012
Showing 1-8 of 8

Last Updated: 09/26/2026